Retained Viscoat and intraocular pressure after phaceomulsification.
OBJECTIVE
A single blind prospective randomised study to determine the effect of Viscoat retained in the eye on intraocular pressure (IOP) after phacoemulsification.


METHODS
82 patients were randomly selected to receive either Viscoat, a viscoelastic composed of 3% sodium hyaluronate (mol wt 500,000 daltons), and 4% chondroitin sulfate (mol wt 25,000 daltons) or Provisc, a viscoelastic compound composed of 1% sodium hyaluronate (mol wt 4,00,000 daltons) during phacoemulsification. In those patients receiving Viscoat the viscoelastic in the anterior chamber only was removed, whereas in those receiving Provisc attempts were made to remove the material entirely. The IOP was measured on the first postoperative day, 16-20 hours after surgery.


RESULTS
The mean postoperative IOP in the Viscoat group was 22.37 +/- 9.0 mmHg and in the Provisc group was 19.67 +/- 6.95 mmHg. Five patients in the Viscoat group had pressure elevations above 30 mmHg as opposed to three in the Provisc group.


CONCLUSIONS
The two viscoelastics cause equivalent pressure elevations postoperatively. In the Viscoat group there were five patients with IOPs above 30 mmHg. We recommend that Viscoat should be aspirated from both the anterior chamber and the capsular bag following routine phacoemulsification.
Watts
P
P
Department of Ophthalmology, Singleton Hospital, Swansea, UK. patrick.watts@net.ntl.com
Austin
M
M
D000368:Aged; D000867:Anterior Chamber; D002807:Chondroitin / Q000008:administration & dosage*; D002809:Chondroitin Sulfates; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects* / Q000502:physiology; D019654:Lens Implantation, Intraocular; D008297:Male; D018918:Phacoemulsification / Q000379:methods; D011184:Postoperative Period; D011446:Prospective Studies; D016037:Single-Blind Method
D004338:Drug Combinations; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D006820:Hyaluronic Acid; D002807:Chondroitin; D002809:Chondroitin Sulfates